Dr. Moore on the Results of the NOVA Trial in Ovarian Cancer

Kathleen Moore, MD
Published: Tuesday, May 23, 2017



Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses the results of the NOVA trial in ovarian cancer.

In the germline BRCA-mutated group, there was a statistically significant positive hazard ratio in favor of niraparib (Zejula), says Moore.

The exploratory endpoints of this trial were to further characterize the germline BRCA-mutated group. A small group of patients with somatic BRCA mutations was identified and they seemed to get the same benefit from niraparib as the BRCA-mutated patients, Moore adds.
 


Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses the results of the NOVA trial in ovarian cancer.

In the germline BRCA-mutated group, there was a statistically significant positive hazard ratio in favor of niraparib (Zejula), says Moore.

The exploratory endpoints of this trial were to further characterize the germline BRCA-mutated group. A small group of patients with somatic BRCA mutations was identified and they seemed to get the same benefit from niraparib as the BRCA-mutated patients, Moore adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x